Mechanisms of action of fluvoxamine for COVID-19: a historical review.
Yaeko HashimotoTakuji SuzukiKenji HashimotoPublished in: Molecular psychiatry (2022)
The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) accelerates the discovery of prophylactic and therapeutic drugs for persons infected with the virus. Drug repurposing for the COVID-19 pandemic has received particular attention. Increasing clinical data suggest that antidepressant use in early-stage subjects with COVID-19 might be associated with a reduced risk of intubation or death. Among the antidepressants, fluvoxamine is the most attractive drug for mild to moderate subjects with COVID-19. In this article, we review the mechanisms of action (i.e., serotonin transporter, sigma-1 receptor, and acid sphingomyelinase) of fluvoxamine for COVID-19. Furthermore, we discuss a possible link between maternal COVID-19 infection and a risk for neuropsychiatric disorders (i.e., autism spectrum disorder and schizophrenia) in offspring.
Keyphrases
- coronavirus disease
- sars cov
- respiratory syndrome coronavirus
- early stage
- autism spectrum disorder
- major depressive disorder
- pregnant women
- working memory
- attention deficit hyperactivity disorder
- high fat diet
- small molecule
- big data
- machine learning
- insulin resistance
- radiation therapy
- electronic health record
- physical activity
- deep learning
- weight gain